Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05363644 Withdrawn - Prostate Cancer Clinical Trials

BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

Start date: May 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess functional outcomes post operatively after the use of BioDFence® G3 during robotic radical prostatectomy.

NCT ID: NCT05191017 Withdrawn - Prostate Cancer Clinical Trials

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

NUV-422-04 is an open-label Phase 1b/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with enzalutamide. The study population is comprised of adults with mCRPC. Patients will self-administer NUV-422 and 160 mg enzalutamide orally in 28-day cycles. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT04781374 Withdrawn - Prostate Cancer Clinical Trials

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: May 21, 2021
Phase: Phase 2
Study type: Interventional

This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment. - The names of the study drug involved in this study is neratinib.

NCT ID: NCT04742972 Withdrawn - Prostate Cancer Clinical Trials

Prostate PMSABR Study

Start date: February 25, 2021
Phase: N/A
Study type: Interventional

In this study, the investigator aim to evaluate the role of PMSA-PET guided SABR on progression free survival (PFS) in patients with oligoprogressive mCRPC with Enzalutamide. The potential improvement in PFS with SABR while continuing the initial-responding Enzalutamide is potentially benefiting to patients in terms of overall disease control.

NCT ID: NCT04486846 Withdrawn - Prostate Cancer Clinical Trials

Electronic Post-Treatment Surveillance Program for Prostate Cancer Survivors (eHealth)

Start date: June 2021
Phase: N/A
Study type: Interventional

The purpose of this single institution pilot study is to determine the feasibility of implementing an eHealth prostate cancer surveillance program through the eVisit electronic medical record patient portal. The investigators will assess patient compliance and satisfaction with eVisit follow up care in lieu of in person clinic visits.

NCT ID: NCT04403568 Withdrawn - Prostate Cancer Clinical Trials

Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate

Start date: October 2021
Phase: Early Phase 1
Study type: Interventional

A proof of concept clinical trial to assess the synergism of curcumin (CURC) and ursolic acid (UA). Before further testing within formal cancer clinical trials, we must (1) evaluate the bioavailability and safety, (2) confirm the presence of metabolites in the target organ, and (3) validate the appropriate mechanism of effect

NCT ID: NCT04339920 Withdrawn - Prostate Cancer Clinical Trials

Spermine Measuring Device Evaluation Protocol

Start date: September 1, 2021
Study type: Observational

Prostate gland is a clinically important male sexual organ and its main function is for the production of semen. Globally, it is the second most common cancer in men globally and is also the fifth cancer cause for death in male. Despite the improvement in the understanding of prostate cancer, the current usage of serum prostate specific antigen (PSA) as a diagnostic marker is still not ideal. Many patients with elevated PSA and then subjected to prostate biopsy were found to have no prostate cancer. Therefore, there is a need to discover new biological markers to improve the current situation in diagnosis and also management of prostate cancer. In our recent studies, urinary spermine levels have been shown to correlate well with prostate cancer diagnosis and cancer aggressiveness. Due to its nature, it could provide a more convenient and non-invasive method for detecting prostate cancer. In order to further improve the accessibility of the test, a simple urine measuring device has been designed to allow more simple and practical usage of the test in clinical setting.The purpose of this study was to evaluate the accuracy of this newly designed urine measuring device for urinary spermine in predicting your prostatic biopsy result.

NCT ID: NCT04296578 Withdrawn - Prostate Cancer Clinical Trials

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Start date: October 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to access the safety of combining sodium selenite with abiraterone and to see what doses of sodium selenite can be safely combined with abiraterone in treating castration resistant prostate cancer.

NCT ID: NCT04272645 Withdrawn - Prostate Cancer Clinical Trials

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Start date: October 2020
Phase: Phase 2
Study type: Interventional

This research is studying two experimental drugs, abemaciclib and atezolizumab, alone and in combination with each other, to learn about the safety and effectiveness of these treatments and their side effects. This is an investigational study treatment for adult men with metastatic castrate resistant prostate cancer (mCRPC) who have progressive disease despite previous treatment with androgen deprivation therapy (ADT). One group of men (men without a genetic mutation called "CDK12 loss") will receive abemaciclib therapy alone. Two other groups of men (men with CDK12 loss in one group and men without CDK12 loss in the other) will receive the combination of abemaciclib and atezolizumab. Another group of men with CDK12 loss will receive atezolizumab therapy alone.

NCT ID: NCT04027270 Withdrawn - Prostate Cancer Clinical Trials

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

Start date: January 2021
Phase: N/A
Study type: Interventional

Patients will be randomized into standard of care or receiving pre and post operative physical therapy intervention following prostatectomy. Outcome measures will be gathered to assess impact of physical therapy on function and quality of life.